Xencor (XNCR) Tops Q4 EPS by 14c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. WDC
3. RNG
4. BYD
5. FIX
6. SPOT
7. BE
8. FCNCA
9. TSCO
10. WCN

Go back to Xencor (XNCR) Tops Q4 EPS by 14c, Revenues Beat

Xencor Reports Fourth Quarter and Full Year 2020 Financial Results

February 23, 2021 4:01 PM EST

-- Management to Host Conference Call at 4:30 p.m. ET Today --

MONROVIA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a review of recent... More